
Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease
A scientist-executive team that, over the last decade, sold one diabetes biotech to Roche for up-to $537 million and two others to Novo Nordisk for undisclosed sums are back with a new company.
University of Indiana biologist Richard DiMarchi and serial entrepreneur Kent Hawryluk have launched MBX Biosciences, raising $36.4 million in a Frazier Healthcare Partners-led round to get it started. For now, the pair are keeping their diseases and drug targets close to the vest, saying only that MBX will develop the same kind of molecules they developed in previous companies — large peptide therapeutics — but with a focus on rare endocrine disorders, as opposed to diabetes.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters